0.960
-0.12 (-11.08%)
| Penutupan Terdahulu | 1.08 |
| Buka | 1.11 |
| Jumlah Dagangan | 815,091 |
| Purata Dagangan (3B) | 731,626 |
| Modal Pasaran | 53,599,772 |
| Harga / Buku (P/B) | 7.54 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2026 |
| EPS Cair (TTM) | -0.940 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 84.79% |
| Nisbah Semasa (MRQ) | 2.33 |
| Aliran Tunai Operasi (OCF TTM) | -34.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.63 M |
| Pulangan Atas Aset (ROA TTM) | -38.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | PDS Biotechnology Corporation | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.38 |
|
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.09% |
| % Dimiliki oleh Institusi | 18.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Inspirion Wealth Advisors, Llc | 31 Mar 2026 | 181,995 |
| Iron Gate Global Advisors Llc | 31 Dec 2025 | 75,016 |
| Tempus Wealth Planning, Llc | 31 Dec 2025 | 61,800 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |